Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Inclusion Criteria: * Patients scheduled for open ventral hernia repair or open colectomy * ASA class I-III * 18 years and older * Subjects with a body mass index (BMI) of \<45kg/m2 and weight less than 150kg * Subjects who have given written informed consent Exclusion Criteria: * Subjects with medical conditions and/or undergoing surgical procedures that are not compatible with the use of the TOF-Watch® SX (e.g., injuries to the thumbs/distal forearms, bilateral ulnar nerve damage or subjects with cardiac pacemaker * Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g., subjects with myasthenia gravis) * Subjects known or suspected to have significant renal dysfunction (e.g. creatinine clearance \< 30 mL.min-1 * Subjects known or suspected to have a (family)history of malignant hyperthermia; have significant hepatic dysfunction * Subjects known or suspected to have an allergy to opiates/opioids, muscle relaxants or other medications used during general anesthesia; * Subjects known or suspected to be hypersensitive to Sugammadex or other cyclodextrins or Rocuronium or any of its excipients * Subjects who have a contraindication to, Rocuronium or Sugammadex * Female subjects who are pregnant * Morbidly obese subjects with a BMI \> 45 kg/m2 or weight more than 150 kg